Kura Oncology (NASDAQ:KURA) Insider Brian Powl Sells 8,891 Shares

Key Points

• Kura Oncology, Inc. insider Brian Powl sold 8,891 shares at $8.94 per share, totaling approximately $79,485, decreasing his ownership by 8.19%.
• The company's stock price is currently $8.97, down 0.9%, with a market capitalization of $778.60 million.
• Kura Oncology reported a quarterly loss of ($0.75) EPS, significantly missing expectations, indicating challenges in meeting revenue forecasts.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Brian Powl sold 8,891 shares of the stock in a transaction on Monday, September 29th. The shares were sold at an average price of $8.94, for a total transaction of $79,485.54. Following the transaction, the insider owned 99,676 shares in the company, valued at $891,103.44. This trade represents a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kura Oncology Stock Down 0.9%

NASDAQ KURA traded down $0.08 during trading hours on Monday, reaching $8.97. 2,168,205 shares of the company traded hands, compared to its average volume of 1,613,537. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $19.93. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $778.60 million, a PE ratio of -3.97 and a beta of 0.19. The company has a 50 day moving average of $7.39 and a two-hundred day moving average of $6.65.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.90). The business had revenue of $15.29 million for the quarter, compared to analysts' expectations of $64.95 million. As a group, equities analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Guggenheim assumed coverage on shares of Kura Oncology in a research report on Thursday, September 4th. They issued a "neutral" rating on the stock. JMP Securities reduced their price target on shares of Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating on the stock in a research report on Monday, August 11th. Cantor Fitzgerald restated an "overweight" rating on shares of Kura Oncology in a research report on Thursday, June 26th. Wall Street Zen upgraded shares of Kura Oncology from a "sell" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, Wedbush restated an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research report on Friday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $24.10.

Institutional Trading of Kura Oncology

Several hedge funds have recently bought and sold shares of the company. BVF Inc. IL increased its stake in Kura Oncology by 202.0% during the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company's stock valued at $51,177,000 after buying an additional 5,186,660 shares during the period. EcoR1 Capital LLC increased its stake in Kura Oncology by 59.1% during the 2nd quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company's stock valued at $24,234,000 after buying an additional 1,559,702 shares during the period. Armistice Capital LLC increased its stake in Kura Oncology by 13.3% during the 1st quarter. Armistice Capital LLC now owns 6,572,000 shares of the company's stock valued at $43,375,000 after buying an additional 772,000 shares during the period. Qube Research & Technologies Ltd increased its stake in Kura Oncology by 63.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company's stock valued at $11,032,000 after buying an additional 738,761 shares during the period. Finally, AQR Capital Management LLC increased its stake in Kura Oncology by 407.8% during the 1st quarter. AQR Capital Management LLC now owns 760,332 shares of the company's stock valued at $5,018,000 after buying an additional 610,604 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.